腺苷A2A受体与帕金森病治疗关系的研究进展
被引量:1
摘要
帕金森病(PD)是一种以中脑黑质致密部多巴胺神经元变性、缺失为主要的病理改变,以静止性震颤、运动迟缓、肌强直和姿势步态异常为主要临床表现的神经系统变性疾病。PD的治疗仍以左旋多巴替代疗法为主,但长期使用多巴胺类药物可引起运动波动、异动症等运动并发症。目前,治疗PD的药物只能缓解症状,不能从根本上阻止多巴胺能神经元的变性、死亡。近年来,腺苷A2A受体拮抗剂倍受关注,有望成为治疗PD的新型药物。现就腺苷A2A受体的分布特点及腺苷A2A受体拈抗剂与PD治疗关系的研究进展作一综述。
出处
《中华老年医学杂志》
CAS
CSCD
北大核心
2008年第4期313-316,共4页
Chinese Journal of Geriatrics
基金
教育部留学回国人员科研启动基金
上海市教育委员会基金(06BZ048)
参考文献22
-
1Masahiko T, Tamakik K, Tetsuya M, et al. Upregulation of striatal adenosine AZA reeptor mRNA in 6-hydroxydopamine-lesioned rats intermittently treated with L-DOPA. Synapse, 2004,52:218-222.
-
2Frederic C, Mehdi D, Oleh H, et al. Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias. Brain, 2004, 127: 1075-1084.
-
3Lee YC,Chien CL, Sun CN, et al. Characterization of the rat A2A adenosine receptor gene: a 4. 8-kb promoter-proximal DNA fragment confers selective expression in the central nervous system. European J Neuroscience, 2003,18 : 1786-1796.
-
4DeMet EM, Chicz DA. Localization of adenosine A2A receptors in rat brain with [3H]ZM-241385. Naunyn Schmiedebergs Arch Pharmacol, 2002, 366: 478-481.
-
5Mori A, Shindou T. Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors. Neur, 2003,61 (Suppl 6) : S44-S48.
-
6Annalisa P, Jadwiga W, Nicola S,et al. New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists. Life Seien,2005,77 : 3259-3267.
-
7Bibbiani F, Oh JD, Petzer JP, et al. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of PD. Exp Neurol, 2003, 184: 285-294.
-
8Coccurello R, Breysse N, Amalric M. Simultaneous blockade of adenosine A2A and metabotropie glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats. Neuropsyehopharmae, 2004,29: 451-1461.
-
9Ekonomou A, Poulou PD, Matsokis N, et al. Stimulation of adenosine A2A receptors elicits zif/268 and NMDA epsilon2 subunit mRNA expression in cortex and striatum of the " weaver" mutant mouse, a genetic model of nigrostriatal dopamine deficiency. Neurosci, 2004,123 : 1025-1036.
-
10Bastia E,Xu YH,Scibelli AC,et al. A crucial role for forebrain adenosine A2A receptors in amphetamine sensitization. Neuropsychopharmac, 2005, 30 : 891-900.
同被引文献58
-
1杨梅,孙圣刚.镁对帕金森病大鼠黑质多巴胺神经元的影响[J].临床神经病学杂志,2008,21(6):437-440. 被引量:7
-
2张静文.帕金森病防治的新靶点[N].中囯医学论坛报,2010-07-22(A2).
-
3Li C, Guo Y, Xie W, et al. Neuroprotection of pramipexole in UPS impairment induced animal model of parkinson's disease [ J ]. Neurochem Res,2010,35 (10) :1546-1556.
-
412th International Congress of Parkinsons Disease and Movement Disorders Abstracts 588 and 592 [ C ]. Presented June,24,2008.
-
5Stern MB, Marek KL, Friedman J, et al. Double-blind, random- ized, controlled trial of rasagiline as monotherapy in early parkin- son's disease patients [ J ]. Mov Disord,2004,19 ( 8 ) :916-923.
-
6Lew MF, Pahwa R, Leahey M, et al. Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of ‘off’ episodes in patients with par- kinsonn's disease [ J ]. Curr Med Res Opin, 2007,23 ( 4 ) : 741 - 750.
-
7Luszczki JJ. Third-generation antiepileptic drugs : mechanisms of action, pharmacokinetics and interactions [ J ]. Pharmacol Rep, 2009,61 (2) :197-216.
-
8Shah U, Hodgson R. Recent progress in the discovery of adenosine A(2A) receptor antagonists for the treatment of parkinson's dis- ease [ J ]. Curr Opin Drug Discov Deve1,2010,13 (4) :466-480.
-
9Jenner P, Mori A, Hauser R, et al. Adenosine, adenosineA2A an- tagonists and parkinsonn's disease [ J ]. Parkinsonism Relat Dis- ord ,2009,15 ( 3 ) :406-413.
-
10Elisabena T, Nieola S, Franeo B, et al. Characterization of the an- tiparkinsonian effects of the new adenosine A2A receptor antago- nist ST1535 :acute and subchrouic smdiesln rats[ J ]. Eur J Phar- maco1,2007,566 ( 1-3 ) :94-102.
-
1张希廉,田军彪,李玉森.帕金森病的现代治疗研究[J].中西医结合心脑血管病杂志,2008,6(8):991-992. 被引量:1
-
2覃兰.帕金森病的治疗进展[J].医学文选,2005,24(4):646-648. 被引量:1
-
3刘振国,戚辰.帕金森病运动并发症及其治疗策略[J].中华医学杂志,2009,89(35):2516-2519. 被引量:11
-
4王惠霞,武新安,何忠芳.帕金森病1例药学监护实践[J].临床合理用药杂志,2012,5(34):85-86. 被引量:5
-
5王宾,陈志斌.生物标志物Nurr1基因对帕金森病早期诊断的研究进展[J].现代医药卫生,2011,27(10):1520-1522.
-
6杨卉,陈生弟.帕金森病治疗的循证医学证据[J].中国现代神经疾病杂志,2007,7(1):39-43. 被引量:2
-
7范景辉,李海燕,周杨.1例帕金森伴异动症患者口服普拉克索致双下肢水肿的病例分析[J].继续医学教育,2015,29(7):114-115. 被引量:1
-
8侯前梅,周小燕,宋丽,彭舒,蒋国会,王晓明.以双下肢震颤为首发症状的帕金森病合并甲状腺功能亢进症漏诊一例[J].临床误诊误治,2016,29(B10):13-14. 被引量:1
-
9刘金龙.脑深部电刺激术治疗帕金森病的临床应用进展[J].新医学,2008,39(6):411-412. 被引量:3
-
10臧矫,邢华.帕金森病实验研究中多巴胺及其合成酶测定方法的研究进展[J].现代医药卫生,2015,31(21):3244-3248. 被引量:1